FOXP1 syndrome is a congenital disorder in which the brain development of affected children is severely impaired due to a genetic variant. A research team from the Medical Faculty Heidelberg at Heidelberg University has now demonstrated in mice, that the inhibition of a specific enzyme in the brain can improve abnormal behavior and immune cell dysfunction in the brain. The results have been published in the journal Advanced Science.

Stem cell-like leukemia cells are responsible for relapses in children and adolescents with a certain type of blood cancer, T-ALL. Researchers at the Hopp Children's Cancer Center Heidelberg (KiTZ), the Molecular Medicine Partnership Unit and the German Cancer Research Center were able to show this in a study. The results could help to overcome resistance in this form of blood cancer and prevent relapses.

Researchers from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg and ETH Zürich have created the first integrated map detailing the metabolic and molecular changes in human blood stem cells as they age, specialize, or turn cancerous. Their innovative research, made possible by highly sensitive low-input techniques, identifies the nutrient choline, as a key player in preserving youthful stem cell traits.

Scientists have been working on the artificial production of blood for several decades. Making a new discovery, researchers from the Institute for Cellular Biology and Immunology Thurgau at the University of Konstanz, in collaboration with Queen Mary University of London, have come an important step closer to this goal.

Colorectal cancer screening programs are currently underutilized in Germany. This also applies to testing for blood in the stool. The immunological stool tests can detect tiny amounts of blood in the stool. Scientists at the German Cancer Research Center (DKFZ) have investigated whether smartphone-based testing could be a meaningful alternative or supplement to traditional laboratory tests.

Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support.

The reservoir of blood stem cells shrinks with age. It becomes increasingly dominated by stem cells that produce immune cells associated with chronic inflammation. Almost all of the 60-year-olds studied show this change. The new discovery could help explain the chronic inflammation that occurs with age and makes us more susceptible to disease. It could also help identify early warning signs of unhealthy aging processes.

Many people are infected with the Epstein-Barr virus (EBV), and most are unaware of it. However, EBV can sometimes cause cancer, and this pathogen also appears to play an important role in multiple sclerosis and other autoimmune diseases. Researchers have discovered that EBV increases the ability of infected immune cells to migrate. In this way, the pathogen promotes its spread in the body – a discovery that may have therapeutic implications.

New treatment methods: DNA origami-based nanodevices precisely control immune response - 24/04/2025

Bottom-up synthetic immunology for novel therapeutic approaches

Modern therapies for combating cancer and infectious diseases increasingly leverage the body’s own immune system. Several research groups at Heidelberg University are using innovative bottom-up approaches in synthetic immunology to develop new treatment methods that can control the immune response more precisely than previously possible.

Contact with pets reduces the risk of developing stress-related disorders in adult life in urban children. This is the conclusion of a study conducted by the Section for Molecular Psychosomatic Medicine at Ulm University Hospital together with other researchers from Germany and the USA. Living with animals is said to alleviate inflammatory stress reactions.

Germany's most important award for young scientists honors the development of immunotherapies against malignant brain tumors.

The Max Planck Society and the Dieter Schwarz Foundation (DSS) have embarked on a groundbreaking initiative. On March 13, 2025, they signed an agreement through which the foundation will support an innovative approach by the Max Planck Institute for Medical Research in Heidelberg to translate basic research findings into practical applications. As part of this endeavour, two new departments of the institute will be established in Heilbronn.

Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication. Scientists work on new approaches to combating highly dangerous viral diseases such as yellow fever or Lassa fever. The European Union is supporting the project over a period of five years to the tune of just under eight million euros.

Pancreatic cancer is fueled by connections to the nervous system. This is reported by scientists from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)*. The team discovered that the tumor reprograms the neurons for its own benefit.

The Gottfried Wilhelm Leibniz-Prize 2025 goes to Prof. Dr Robert Zeiser for his outstanding research in haematology and immunology. Zeiser’s research at the University of Freiburg and the Medical Center – University of Freiburg have led, among other things, to new types of cancer therapy that has increased survival rates and the patients’ quality of life.

On 25 November, the German Research Foundation (DFG) announced the continued funding of two existing Collaborative Research Centres (CRC) at the University of Freiburg’s Faculty of Medicine. In CRC 1453 Nephrogenetics (NephGen), doctors and researchers are using genetic information to search for mechanisms underlying kidney diseases.

3D tumor models, simulations of drug responses or plant stems used for testing heart stents: the 3R-BioMedicUS center at the University of Stuttgart is developing innovative biomedical approaches to improve preclinical studies, to be seen in the new video.

Chronic inflammatory bowel diseases - 25/09/2024

Proinflammatory regulatory T lymphocytes as a therapeutic target in Crohn's disease

Chronic inflammatory bowel diseases are very stressful for those affected and increase the risk of bowel cancer. PD Dr. Robyn Laura Kosinsky from the Bosch Health Campus in Stuttgart, together with researchers from the USA, identified disfunctional regulatory T cells as important drivers of inflammation in Crohn's disease. They also found that with the help of an epigenetically active drug, it was possible to restore the cells’ original…

Synthetic immunology is the topic of an article in the “Perspectives” section of the journal “Nature Nanotechnology”. Herein, Heidelberg researchers describe a so-called bottom-up approach that uses the toolbox of nanotechnology and synthetic biology to construct systems from molecular building blocks and specifically equip them with immune functions.

Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…

A cutting-edge chemical process is the first to make it possible to quickly and easily produce modified peptides with boronic acids. As part of this work, scientists managed to synthesize a large number of different biologically active peptide boronic acids and investigate their properties. They open up new possibilities in the young research field of synthetic immunology and could go on to be used primarily in immunotherapy.

TWYCE GmbH - 10/07/2024

Better immune response against prostate cancer thanks to new bispecific antibodies

TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

With "OrgaPlexing", scientists at the MPI of Immunobiology and Epigenetics have developed a new method that shows how guardian cells of the immune system, the macrophages, orchestrate their cell structures during inflammation or bacterial infection, making it possible to observe the interactions between several organelles simultaneously and thus providing insights into cell metabolism and the production of inflammatory molecules.

The Baden-Württemberg Ministry of Science, Research and Arts (MWK) is supporting medical researchers at Ulm University with start-up funding totalling 600,000 euros. The aim is to establish an EU consortium for the broad therapeutic use of mesenchymal stromal cells. The funding is being awarded as part of the "BEGIN - Participation in major European projects and initiatives" programme.